Key result
Recent advancements in the pathophysiology, biomarkers, genetics, and specific medical and surgical treatments for pulmonary arterial hypertension highlight the need for accurate etiological diagnosis.
Why the study?
Despite progress in diagnosis and treatment, pulmonary arterial hypertension remains a progressive disease with significant mortality, necessitating accurate etiological diagnosis, treatment, and prognosis judgment.
This review summarizes recent advancements in the pathophysiology, biomarkers, genetics, and targeted therapies for pulmonary arterial hypertension.
Synthesizes recent PAH advancements; leaves open prospective validation before clinical integration.
Pulmonary arterial hypertension (PAH) is a progressive disease. Although great progress has been made in its diagnosis and treatment in recent years, its mortality rate is still very significant. The pathophysiology and pathogenesis of PAH are complex and involve endothelial dysfunction, chronic inflammation, smooth muscle cell proliferation, pulmonary arteriole occlusion, antiapoptosis and pulmonary vascular remodeling. These factors will accelerate the progression of the disease, leading to poor prognosis. Therefore, accurate etiological diagnosis, treatment and prognosis judgment are particularly important. Here, we systematically review the pathophysiology, diagnosis, genetics, prognosis and treatment of PAH.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted a review in Pulmonary arterial hypertension. Recent advancements in the pathophysiology, biomarkers, genetics, and specific medical and surgical treatments for pulmonary arterial hypertension highlight the need for accurate etiological diagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: